Literature DB >> 14700647

Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial.

Roy W Beck1, Robin L Gal, M Tariq Bhatti, Michael C Brodsky, Edward G Buckley, Georgia A Chrousos, James Corbett, Eric Eggenberger, James A Goodwin, Barrett Katz, David I Kaufman, John L Keltner, Mark J Kupersmith, Neil R Miller, Pamela S Moke, Sarkis Nazarian, Silvia Orengo-Nania, Peter J Savino, William T Shults, Craig H Smith, Jonathan D Trobe, Michael Wall, Dongyuan Xing.   

Abstract

PURPOSE: To assess visual function more than 10 years after an episode of optic neuritis in patients enrolled in the Optic Neuritis Treatment Trial.
DESIGN: Longitudinal follow-up of a randomized clinical trial.
METHODS: Vision testing included measures of visual acuity, contrast sensitivity, and visual field. Quality of life was assessed with the National Eye Institute Visual Function Questionnaire.
RESULTS: Examinations were completed on 319 patients. In most patients, visual function test results in the eyes that experienced optic neuritis at study entry ("affected eyes") were normal or only slightly abnormal after 9.9 to 13.7 years. Visual acuity in the affected eyes was >or=20/20 in 74%, 20/25 to 20/40 in 18%, <20/40 to 20/200 in 5%, and <20/200 in 3%. On average, visual function was worse in patients with multiple sclerosis (MS) than in those without MS. Recurrent optic neuritis in either eye occurred in 35% of patients. Such attacks were more frequent in patients with MS (P <.001). The National Eye Institute Visual Function Questionnaire scores were lower when visual acuity was abnormal and when MS was present.
CONCLUSIONS: Most patients retained good to excellent vision more than 10 years after an attack of optic neuritis. Recurrences were more frequent in patients with MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14700647     DOI: 10.1016/s0002-9394(03)00862-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  57 in total

1.  CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis.

Authors:  Henrik Horwitz; Matilda Degn; Signe Modvig; Henrik B W Larsson; Benedikte Wanscher; Jette L Frederiksen
Journal:  J Neurol       Date:  2012-06-06       Impact factor: 4.849

Review 2.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2015-08-14

Review 3.  Corticosteroids for treating optic neuritis.

Authors:  S S Vedula; S Brodney-Folse; R L Gal; R Beck
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  [New aspects in the therapy of multiple sclerosis and optic neuritis].

Authors:  W Lagrèze; R Diem
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

5.  [Multiple sclerosis. An update with practical guidelines for ophthalmologists].

Authors:  T Ziemssen; H Wilhelm; F Ziemssen
Journal:  Ophthalmologe       Date:  2006-07       Impact factor: 1.059

6.  New developments in the treatment of optic neuritis.

Authors:  Thomas M Jenkins; Ahmed T Toosy
Journal:  Eye Brain       Date:  2010-06-17

7.  How Common Is Signal-Intensity Increase in Optic Nerve Segments on 3D Double Inversion Recovery Sequences in Visually Asymptomatic Patients with Multiple Sclerosis?

Authors:  T Sartoretti; E Sartoretti; S Rauch; C Binkert; M Wyss; D Czell; S Sartoretti-Schefer
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-29       Impact factor: 3.825

8.  Association of race/ethnicity with visual outcomes following acute optic neuritis: an analysis of the Optic Neuritis Treatment Trial.

Authors:  Heather E Moss; Weihua Gao; Laura J Balcer; Charlotte E Joslin
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

9.  Patients' knowledge and perception on optic neuritis management before and after an information session.

Authors:  Albert I Matti; Miriam C Keane; Helen McCarl; Pamela Klaer; Celia S Chen
Journal:  BMC Ophthalmol       Date:  2010-03-21       Impact factor: 2.209

10.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.